NEUROPHARMACOLOGY AND NEUROTOXICOLOGYSimvastatin treatment prolongs the survival of scrapie-infected miceKempster, Saraha; Bate, Cliveb; Williams, AlunbAuthor Information aDepartment of Obstetrics and Gynaecology, University of Cambridge, Rosie Hospital, Robinson Way, Cambridge bDepartment of Pathology and Infectious Diseases, Royal Veterinary College, Hawkshead Lane, North Mymms, Hatfield, UK Correspondence to Dr Clive Bate, Department of Pathology and Infectious Diseases, Royal Veterinary College, Hawkshead Lane, North Mymms, Hatfield, AL9 7TA, UK Tel: +01707 666550; fax: +01707 661464; e-mail: email@example.com Received 29 November 2006; accepted 15 December 2006 NeuroReport: March 26th, 2007 - Volume 18 - Issue 5 - p 479-482 doi: 10.1097/WNR.0b013e328058678d Buy SDC Metrics Abstract Statins, drugs that decrease cholesterol biosynthesis, are known to reduce the formation of the disease-associated isoform of the prion protein (PrPSc) in neuroblastoma cells in vitro. In this study, we report the effects of simvastatin, a clinically approved statin that penetrates the brain, on mice infected with the ME7 strain of scrapie. The decline in motor functions associated with scrapie infection was delayed in mice receiving (1 mg/kg) simvastatin, a dosage used to treat hypercholesterolemia in humans. Simvastatin treatment also significantly prolonged the survival times of infected mice (193 vs. 183 days). These results indicate that low-dosage simvastatin treatment affects the progression of experimental scrapie, and supports the concept that statin treatment may influence the prion pathogenesis. © 2007 Lippincott Williams & Wilkins, Inc.